DOCSLIB.ORG

Differential Regulation of Metzincins in Experimental Chronic Renal Allograft

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Differential Regulation of Metzincins in Experimental Chronic Renal Allograft View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector original article http://www.kidney-international.org & 2006 International Society of Nephrology Differential regulation of metzincins in experimental chronic renal allograft rejection: Potential markers and novel therapeutic targets CC Berthier1,2,8, N Lods1,8, SA Joosten3, C van Kooten3, D Leppert4, RLP Lindberg4, A Kappeler5, F Raulf6, EE Sterchi7, D Lottaz7 and H-P Marti1 1Division of Nephrology/Hypertension, Inselspital, University of Bern, Bern, Switzerland; 2Division of Nephrology, University Hospital of Zu¨rich, Zu¨rich, Switzerland; 3Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Neurology, University of Basel, Basel, Switzerland; 5Institute of Pathology, University of Bern, Bern, Switzerland; 6Department of Transplantation, Novartis Institutes of BioMedical Research, Basel, Switzerland and 7Institute of Biochemistry and Molecular Biology, University of Bern, Bern, Switzerland Chronic renal allograft rejection is characterized by chronic renal allograft rejection. Thus, an altered pattern of alterations in the extracellular matrix compartment and in metzincins may represent novel diagnostic markers and the proliferation of various cell types. These features are possibly may provide novel targets for future therapeutic controlled, in part by the metzincin superfamily of interventions. metallo-endopeptidases, including matrix metalloproteinases Kidney International (2006) 69, 358–368. doi:10.1038/sj.ki.5000049 (MMPs), a disintegrin and metalloproteinase (ADAM) and KEYWORDS: chronic rejection; matrix metalloproteinases; meprin; meprin. Therefore, we investigated the regulation of metzincins; renal allograft; tissue inhibitors of metalloproteinases metzincins in the established Fisher to Lewis rat kidney transplant model. Studies were performed using frozen The two main causes responsible for late renal allograft homogenates and paraffin sections of rat kidneys at day 0 failure are chronic rejection, a major contributor to chronic (healthy controls) and during periods of chronic rejection at allograft nephropathy, and patient death with a functioning day þ 60 and day þ 100 following transplantation. The transplant.1 Therapy and precise diagnosis of chronic messenger RNA (mRNA) expression was examined by rejection remain difficult. Therefore, the definition of new Affymetrix Rat Expression Array 230A GeneChip and by diagnostic markers and of novel therapeutic targets continue real-time Taqman polymerase chain reaction analyses. to be of great clinical relevance. Protein expression was studied by zymography, Western blot Alterations in the extracellular matrix (ECM) compartment analyses, and immunohistology. mRNA levels of MMPs and in the proliferation rates of various cell types are key (MMP-2/-11/-12/-14), of their inhibitors (tissue inhibitors of features in chronic allograft nephropathy, including chronic metalloproteinase (TIMP)-1/-2), ADAM-17 and transforming rejection processes.2 The metabolism of ECM proteins in the growth factor (TGF)-b1 significantly increased during kidney is influenced substantially by the metzincin superfamily chronic renal allograft rejection. MMP-2 activity and of metalloendopeptidases, notably by matrix metalloprotein- immunohistological staining were augmented accordingly. ases (MMPs)3,4 and to some extent also by meprin5–7 and by a The most important mRNA elevation was observed in the disintegrin and metalloproteinases (ADAMs).8,9 case of MMP-12. As expected, Western blot analyses also MMPs are traditionally classified into four categories, demonstrated increased production of MMP-12, MMP-14, namely interstitial collagenases (MMP-1/-8/-13), gelatinases and TIMP-2 (in the latter two cases as individual proteins and (MMP-2/-9), stromelysins (MMP-3/-7/-10/-11/-12) and as complexes). In contrast, mRNA levels of MMP-9/-24 and membrane-type -MMP (MMP-14/-15/-16/-17).10,11 meprin a/b had decreased. Accordingly, MMP-9 protein levels The main function of MMPs is the degradation of ECM and meprin a/b synthesis and activity were downregulated proteins and to a lesser extent the regulation of cell significantly. Members of metzincin families (MMP, ADAM, proliferation.4,12–14 Reversible MMP inhibition occurs by and meprin) and of TIMPs are differentially regulated in their natural inhibitors, tissue inhibitors of metalloprotein- ases (TIMPs).15 MMPs represent important mediators in Correspondence: H-P Marti, Division of Nephrology/Hypertension, Inselspi- inflammatory diseases and also in tumor invasion, kidney tal Bern, 3010 Bern, Switzerland. E-mail: [email protected] morphogenesis and bone turnover.3,11,16–20 8Both these authors contributed equally to this investigation. MMPs may act as proinflammatory mediators in allograft 10,11 Received 25 May 2004; revised 24 June 2005; accepted 11 August 2005 rejection in several ways: direct tissue injury, augmenta- 358 Kidney International (2006) 69, 358–368 CC Berthier et al.: Metzincins in renal allograft rejection original article tion of cell proliferation and/or migration4,14,21 and facilita- for several days, followed by chronic rejection beyond day tion of tissue invasion by extrinsic cells (e.g. leukocytes).20 þ 50 after transplantation. Chronic rejection is characterized Meprin represents either a cell-surface bound or a secreted by severe histological alterations as well as by increases in zinc endopeptidase of the astacin family of the metzincins.5–7,22 microalbuminuria and serum creatinine levels, as shown in This protease is composed of a and b subunits of Figure 1 and Table 1, and as previously reported.29,30 approximately 85–110 kDa, respectively, that form homo- and hetero-oligomeric complexes.7,23 Rat meprin A exists either as Affymetrix GeneChip analysis homo-oligomers of a subunits or as heterodimers or tetramers Results of Affymetrix Rat Expression Array 230A GeneChip of a and b subunits.7,23 On the contrary, rat meprin B consists analysis are summarized in Table 2. Significant upregulation essentially of homo-oligomeric b subunits.7,23 Only the homo- was observed for MMP-11/-12/-14, ADAM-17, TIMP-1/-2 oligomers of meprin A are secreted proteins.7 Meprin B and and transforming growth factor (TGF)-b1 during chronic hetero-oligomers of meprin A remain membrane bound.7 rejection at day þ 60 and day þ 100 (with the exception Meprin is highly regulated and is strongly expressed at the of ADAM-17 and MMP-11). Levels of these two proteases brush border membranes of renal proximal tubular cells and failed to reach statistical significance at a later time point intestinal epithelial cells.5,24 Meprin cleaves a wide range of (day þ 100). peptides and proteins, including collagen type IV, laminin, In contrast, MMP-9 and meprin a messenger RNA fibronectin, and nidogen.22–25 (mRNA) substantially decreased as a result of the chronic With respect to the kidney, meprin has been investigated rejection process at both time points and MMP-24 was in experimental ischemia and reperfusion injury.5,26 Mice reduced significantly at day þ 60. expressing lower meprin A levels in the kidney showed a MMP-2/-3/-7/-8/-10/-16/-23, ADAM-10 and TIMP-3 gene decreased degree of renal damage as a result of ischemia and expression remained unchanged during the rejection process. reperfusion.27 Meprin was found to be cytotoxic to renal To complete our studies, we investigated selected metzin- tubular epithelial cells and its inhibition by actinonin cin substrates, as shown in Table 2. As expected from the ameliorated ischemia–reperfusion injury in rats.5 histological alterations commonly seen in chronic allograft The ADAMs represent a family of membrane proteins rejection and from previous descriptions of our model,29,30 containing a disintegrin and metalloprotease domain.8,9 The main substrates of ADAM are integral membrane or ECM proteins. Altered ADAM expression has been found in several disorders including asthma, arthritis, Alzheimer’s disease, Day 0 Day + 60 Day +100 atherosclerosis, and malignancy.8,9 We focused on ADAM-17 (tumour necrosis factor-a converting enzyme) due to its prominent role in inflammation.28 In our present studies, we analyzed the regulation of a wide spectrum of metzincins in the Fisher (F344) to Lewis (LEW) kidney transplant model.29,30 Two time points of chronic rejection were chosen, days þ 60 and þ 100 after transplantation.29,30 RESULTS F344 to LEW renal transplant model Figure 1 | Renal histology. Left panel: healthy control kidney (day 0). For our studies, we used the well-established F344 to LEW Middle panel: chronic rejection of an F344 renal allograft at day þ 60 kidney transplant model. This experimental model has been demonstrating glomerular and tubulo-interstitial alterations, as 29,30 scored in Table 1 (Periodic acid-Schiff staining). Right panel: chronic extensively described in the past. Importantly, LEW rejection at day þ 100 depicting similar histological alterations, as recipients develop acute rejection at approximately day þ 25 compared to day þ 60. Table 1 | Histological and functional characteristics of chronic allograft rejection Interstitial infiltrate, tubular atrophy, fibrin in glomeruli, Arterial Creatinine mesangiolysis, Interstitial fibrointimal Microalbuminurea7s.d. (serum)7s.d. glomerulitis fibrosis hyperplasia (mg/24 h) (lmol/l) Day 0a 0b 0b 0b 0.570.13 48.6773.06 Days +60 to +100c 2b 3b 1b 10.5179.74 79.43710.47 an=8. bBanff classification.29,31 cn=12 (day +60) and n=6 (day +100). Kidney International (2006) 69, 358–368 359 original article CC Berthier et al.: Metzincins in renal allograft rejection Table 2 | Affymetrix GeneChip analysis of 25 genes (12 MMP, three TIMP, two ADAM, two meprins, TGF-b1, four collagens, and a proteoglycan core protein) expressed in allografts with chronic rejection (samples at day +60 and day +100) and in healthy kidney controls (samples at day 0) RefSeq/GenBank Affymetrix Gene accession no. probe set Day 0 Day +60 Day +100 MMP-2 NM_031054 1369825_at 23.877.6 18.676.3 15.574.2 MMP-3 NM_133523 1368657_at 15.775.6 18.979.6 14.577.2 MMP-7 a NM_012864 1368766_at 2.371.0a 18.579.3a 8.
Load more

Recommended publications
  • The Metalloproteases Meprin Α and Meprin Β: Unique Enzymes In
    Biochem. J. (2013) 450, 253–264 (Printed in Great Britain) doi:10.1042/BJ20121751 253 REVIEW ARTICLE The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis Claudia BRODER and Christoph BECKER-PAULY1 Institute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, Rudolf-Hober-Str.¨ 1, Kiel 24118, Germany The metalloproteases meprin α and meprin β exhibit structural peptides is thought to be the major cause of the neurodegenerative and functional features that are unique among all extracellular Alzheimer’s disease. On the other hand, ADAM10 (a disintegrin proteases. Although meprins were discovered more than 30 years and metalloprotease domain 10), which is the constitutive α- ago, their precise substrates and physiological roles have been secretase, was shown to be activated by meprin β, which is itself elusive. Both enzymes were originally found to be highly shed from the cell surface by ADAM10. In skin, both meprins expressed in kidney and intestine, which focused research are overexpressed in fibrotic tumours, characterized by massive on these particular tissues and associated pathologies. Only accumulation of fibrillar collagens. Indeed, procollagen III is recently it has become evident that meprins exhibit a much processed to its mature form by meprin α and meprin β,an broader expression pattern, implicating functions in angiogenesis, essential step in collagen fibril assembly. The recently solved cancer, inflammation, fibrosis and neurodegenerative diseases. crystal structure of meprin β and the unique cleavage specificity Different animal models, as well as proteomics approaches for of these proteases identified by proteomics will help to generate the identification of protease substrates, have helped to reveal specific inhibitors that could be used as therapeutics to target more precise molecular signalling events mediated by meprin meprins under certain pathological conditions.
    [Show full text]
  • Discovery and Optimization of Selective Inhibitors of Meprin Α (Part II)
    pharmaceuticals Article Discovery and Optimization of Selective Inhibitors of Meprin α (Part II) Chao Wang 1,2, Juan Diez 3, Hajeung Park 1, Christoph Becker-Pauly 4 , Gregg B. Fields 5 , Timothy P. Spicer 1,6, Louis D. Scampavia 1,6, Dmitriy Minond 2,7 and Thomas D. Bannister 1,2,* 1 Department of Molecular Medicine, Scripps Research, Jupiter, FL 33458, USA; [email protected] (C.W.); [email protected] (H.P.); [email protected] (T.P.S.); [email protected] (L.D.S.) 2 Department of Chemistry, Scripps Research, Jupiter, FL 33458, USA; [email protected] 3 Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA; [email protected] 4 The Scripps Research Molecular Screening Center, Scripps Research, Jupiter, FL 33458, USA; [email protected] 5 Unit for Degradomics of the Protease Web, Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str.1, 24118 Kiel, Germany; fi[email protected] 6 Department of Chemistry & Biochemistry and I-HEALTH, Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA 7 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3301 College Avenue, Fort Lauderdale, FL 33314, USA * Correspondence: [email protected] Abstract: Meprin α is a zinc metalloproteinase (metzincin) that has been implicated in multiple diseases, including fibrosis and cancers. It has proven difficult to find small molecules that are capable Citation: Wang, C.; Diez, J.; Park, H.; of selectively inhibiting meprin α, or its close relative meprin β, over numerous other metzincins Becker-Pauly, C.; Fields, G.B.; Spicer, which, if inhibited, would elicit unwanted effects.
    [Show full text]
  • Structural Basis for the Sheddase Function of Human Meprin Β Metalloproteinase at the Plasma Membrane
    Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane Joan L. Arolasa, Claudia Broderb, Tamara Jeffersonb, Tibisay Guevaraa, Erwin E. Sterchic, Wolfram Boded, Walter Stöckere, Christoph Becker-Paulyb, and F. Xavier Gomis-Rütha,1 aProteolysis Laboratory, Department of Structural Biology, Molecular Biology Institute of Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona Science Park, E-08028 Barcelona, Spain; bInstitute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, D-24118 Kiel, Germany; cInstitute of Biochemistry and Molecular Medicine, University of Berne, CH-3012 Berne, Switzerland; dArbeitsgruppe Proteinaseforschung, Max-Planck-Institute für Biochemie, D-82152 Planegg-Martinsried, Germany; and eInstitute of Zoology, Cell and Matrix Biology, Johannes Gutenberg-University, D-55128 Mainz, Germany Edited by Brian W. Matthews, University of Oregon, Eugene, OR, and approved August 22, 2012 (received for review June 29, 2012) Ectodomain shedding at the cell surface is a major mechanism to proteolysis” step within the membrane (1). This is the case for the regulate the extracellular and circulatory concentration or the processing of Notch ligand Delta1 and of APP, both carried out by activities of signaling proteins at the plasma membrane. Human γ-secretase after action of an α/β-secretase (11), and for signal- meprin β is a 145-kDa disulfide-linked homodimeric multidomain peptide peptidase, which removes remnants of the secretory pro- type-I membrane metallopeptidase that sheds membrane-bound tein translocation from the endoplasmic membrane (13). cytokines and growth factors, thereby contributing to inflammatory Recently, human meprin β (Mβ) was found to specifically pro- diseases, angiogenesis, and tumor progression.
    [Show full text]
  • Metalloprotease Meprinb in Rat Kidney: Glomerular Localization and Differential Expression in Glomerulonephritis
    Metalloprotease Meprinb in Rat Kidney: Glomerular Localization and Differential Expression in Glomerulonephritis Beatrice Oneda1., Nade`ge Lods1., Daniel Lottaz1¤, Christoph Becker-Pauly2, Walter Sto¨ cker2, Jeffrey Pippin3, Maya Huguenin1, Daniel Ambort1, Hans-Peter Marti4, Erwin E. Sterchi1* 1 Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland, 2 Institute of Zoology, Johannes Gutenberg University, Mainz, Germany, 3 Division of Nephrology, University of Washington, Seattle, Washington, United States of America, 4 Division of Nephrology/Hypertension, Inselspital, University of Bern, Bern, Switzerland Abstract Meprin (EC 3.4.24.18) is an oligomeric metalloendopeptidase found in microvillar membranes of kidney proximal tubular epithelial cells. Here, we present the first report on the expression of meprinb in rat glomerular epithelial cells and suggest a potential involvement in experimental glomerular disease. We detected meprinb in glomeruli of immunostained rat kidney sections on the protein level and by quantitative RT-PCR of laser-capture microdissected glomeruli on the mRNA level. Using immuno-gold staining we identified the membrane of podocyte foot processes as the main site of meprinb expression. The glomerular meprinb expression pattern was altered in anti-Thy 1.1 and passive Heymann nephritis (PHN). In addition, the meprinb staining pattern in the latter was reminiscent of immunostaining with the sheep anti-Fx1A antiserum, commonly used in PHN induction. Using Western blot and immunoprecipitation assays we demonstrated that meprinb is recognized by Fx1A antiserum and may therefore represent an auto-antigen in PHN. In anti-Thy 1.1 glomerulonephritis we observed a striking redistribution of meprinb in tubular epithelial cells from the apical to the basolateral side and the cytosol.
    [Show full text]
  • Metalloproteases Meprin Α and Meprin Β Are C- and N-Procollagen Proteinases Important for Collagen Assembly and Tensile Strength
    Metalloproteases meprin α and meprin β are C- and N-procollagen proteinases important for collagen assembly and tensile strength Claudia Brodera, Philipp Arnoldb, Sandrine Vadon-Le Goffc, Moritz A. Konerdingd, Kerstin Bahrd, Stefan Müllere, Christopher M. Overallf, Judith S. Bondg, Tomas Koudelkah, Andreas Tholeyh, David J. S. Hulmesc, Catherine Moalic, and Christoph Becker-Paulya,1 aUnit for Degradomics of the Protease Web, Institute of Biochemistry, University of Kiel, 24118 Kiel, Germany; bInstitute of Zoology, Johannes Gutenberg University, 55128 Mainz, Germany; cTissue Biology and Therapeutic Engineering Unit, Centre National de la Recherche Scientifique/University of Lyon, Unité Mixte de Recherche 5305, Unité Mixte de Service 3444 Biosciences Gerland-Lyon Sud, 69367 Lyon Cedex 7, France; dInstitute of Functional and Clinical Anatomy, University Medical Center, Johannes Gutenberg University, 55128 Mainz, Germany; eDepartment of Gastroenterology, University of Bern, CH-3010 Bern, Switzerland; fCentre for Blood Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; gDepartment of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA 17033; and hInstitute of Experimental Medicine, University of Kiel, 24118 Kiel, Germany Edited by Robert Huber, Max Planck Institute of Biochemistry, Planegg-Martinsried, Germany, and approved July 9, 2013 (received for review March 22, 2013) Type I fibrillar collagen is the most abundant protein in the human formation (22). A tight balance between synthesis and break- body, crucial for the formation and strength of bones, skin, and down of ECM is required for the function of all tissues, and tendon. Proteolytic enzymes are essential for initiation of the dysregulation leads to pathophysiological events, such as arthri- assembly of collagen fibrils by cleaving off the propeptides.
    [Show full text]
  • Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling
    www.nature.com/scientificreports OPEN Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Received: 07 October 2016 Accepted: 03 February 2017 Trans-Signaling Published: 09 March 2017 Philipp Arnold1, Inga Boll2, Michelle Rothaug2, Neele Schumacher2, Frederike Schmidt2, Rielana Wichert2, Janna Schneppenheim1, Juliane Lokau2, Ute Pickhinke2, Tomas Koudelka3, Andreas Tholey3, Björn Rabe2, Jürgen Scheller4, Ralph Lucius1, Christoph Garbers2, Stefan Rose-John2 & Christoph Becker-Pauly2 Soluble Interleukin-6 receptor (sIL-6R) mediated trans-signaling is an important pro-inflammatory stimulus associated with pathological conditions, such as arthritis, neurodegeneration and inflammatory bowel disease. The sIL-6R is generated proteolytically from its membrane bound form and A Disintegrin And Metalloprotease (ADAM) 10 and 17 were shown to perform ectodomain shedding of the receptor in vitro and in vivo. However, under certain conditions not all sIL-6R could be assigned to ADAM10/17 activity. Here, we demonstrate that the IL-6R is a shedding substrate of soluble meprin α and membrane bound meprin β, resulting in bioactive sIL-6R that is capable of inducing IL-6 trans- signaling. We determined cleavage within the N-terminal part of the IL-6R stalk region, distinct from the cleavage site reported for ADAM10/17. Interestingly, meprin β can be shed from the cell surface by ADAM10/17 and the observation that soluble meprin β is not capable of shedding the IL-6R suggests a regulatory mechanism towards trans-signaling. Additionally, we observed a significant negative correlation of meprin β expression and IL-6R levels on human granulocytes, providing evidence for in vivo function of this proteolytic interaction.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • Os9) and the Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, in Kidney Tubular Cells
    North Carolina Agricultural and Technical State University Aggie Digital Collections and Scholarship Theses Electronic Theses and Dissertations 2013 Meprin Interaction With Osteosarcoma 9 (Os9) And The Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, In Kidney Tubular Cells Barry L. Martin North Carolina Agricultural and Technical State University Follow this and additional works at: https://digital.library.ncat.edu/theses Recommended Citation Martin, Barry L., "Meprin Interaction With Osteosarcoma 9 (Os9) And The Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, In Kidney Tubular Cells" (2013). Theses. 287. https://digital.library.ncat.edu/theses/287 This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at Aggie Digital Collections and Scholarship. It has been accepted for inclusion in Theses by an authorized administrator of Aggie Digital Collections and Scholarship. For more information, please contact [email protected]. Meprin Interaction with Osteosarcoma 9 (OS9) and the Hypoxia Response Gene, Hypoxia- inducible Factor 1 (HIF1) Alpha, in Kidney Tubular Cells Barry L. Martin North Carolina A&T State University A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Department: Biology Major: Biology Major Professor: Dr. Elimelda Moige Ongeri Greensboro, North Carolina 2013 i School of Graduate Studies North Carolina Agricultural and Technical State University This is to certify that the Master’s Thesis of Barry L. Martin has met the thesis requirements of North Carolina Agricultural and Technical State University Greensboro, North Carolina 2013 Approved by: Elimelda Moige Ongeri, PhD Jian Han, PhD Major Professor Committee Member Catherine White, PhD Scott Harrison, PhD Committee Member Committee Member Mary Smith, PhD Sanjiv Sarin, PhD Department Chair Dean, The Graduate School ii © Copyright by Barry L.
    [Show full text]
  • MEP1A Allele for Meprin a Metalloprotease Is a Susceptibility Gene for Inflammatory Bowel Disease
    ARTICLES nature publishing group See COMMENTARY page XX MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease S B a n e r j e e 1 , 8 , B O n e d a 2 , 8 , L M Ya p 3 , 9 , D P J e w e l l 4 , G L M a t t e r s 1 , L R F it5 z p a , t r ic k F 6 S e , ib o l dE E 2 , S t e r c h i T A h m a d 7 , D L o t t a z 2,10 a n d J S B o n d 1 The MEP1A gene, located on human chromosome 6p (mouse chromosome 17) in a susceptibility region for inflammatory bowel disease (IBD), encodes the -subunit of metalloproteinase meprin A, which is expressed in the intestinal epithelium. This study shows a genetic association of MEP1A with IBD in a cohort of ulcerative colitis (UC) patients. There were four single-nucleotide polymorphisms in the coding region (P = 0.0012 – 0.04), and one in the 3 Ј -untranslated region ( P = 2 × 10 − 7 ) that displayed associations with UC. Moreover, meprin- mRNA was decreased in inflamed mucosa of IBD patients. Meprin- knockout mice exhibited a more severe intestinal injury and inflammation than their wild-type counterparts following oral administration of dextran sulfate sodium. Collectively, the data implicate MEP1A as a UC susceptibility gene and indicate that decreased meprin- expression is associated with intestinal inflammation in IBD patients and in a mouse experimental model of IBD.
    [Show full text]